Should you buy DaVita (DVA)?
Updated
DaVita delivers consistent earnings beats and strong cash generation, but the stock has moved above analyst consensus targets and carries concentrated exposure to government reimbursement programs representing roughly two-thirds of revenue; the setup favors waiting for a pullback that restores a more favorable entry.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Engine methodology range
Range computation requires sufficient peer-comparable data; available for tickers with peer_count ≥3.
What the engine is tracking
| Pillar | Expectation | Trend |
|---|---|---|
Approximately 68% of revenue derives from government-based programs including Medicare and Medicare Advantage, meaning any adverse policy change or reimbursement-rate adjustment by government payers could have a disproportionately large impact on profitability. Bear case | Government-based program revenue mix declines below 65% as commercial payer relationships expand over the next 12 months. | →Stable |
| CounterThree beats in the last four quarters — including a 23% positive surprise in the most recent period — demonstrate the company is navigating the current reimbursement environment effectively, and the concentration risk may already be reflected in investor expectations. | ||
Three earnings beats in the last four quarters — including a 23% positive surprise in the most recent reporting period — combined with upward-trending analyst estimates suggest the company is consistently outperforming expectations and building a constructive earnings trajectory. Earnings | The company delivers at least one additional earnings beat in the next two reporting periods, sustaining the positive surprise pattern. | →Stable |
| CounterThe single miss in the last four quarters came in at roughly 21% below estimates, demonstrating that earnings can disappoint sharply; a repeat, particularly in a name carrying 15% short interest, could trigger an outsized negative reaction. | ||
At $209.75, the stock is trading above the analyst consensus target of $207.56, meaning the near-term risk/reward geometry is unfavorable; the setup suggests patience rather than initiating new exposure at current prices. Warnings | Analyst consensus price targets rise above $230 within two quarterly revision cycles following continued earnings beats, restoring meaningful positive upside. | →Stable |
| CounterStrong technical momentum — golden cross, price above all key moving averages, RSI at 68, and rising on-balance volume — suggests institutional buyers continue to push the stock higher and that consensus targets may be stale rather than a binding ceiling. | ||
Approximately 68% of revenue derives from government-based programs including Medicare and Medicare Advantage, meaning any adverse policy change or reimbursement-rate adjustment by government payers could have a disproportionately large impact on profitability.
→Stable- Expectation
- Government-based program revenue mix declines below 65% as commercial payer relationships expand over the next 12 months.
CounterThree beats in the last four quarters — including a 23% positive surprise in the most recent period — demonstrate the company is navigating the current reimbursement environment effectively, and the concentration risk may already be reflected in investor expectations.
Three earnings beats in the last four quarters — including a 23% positive surprise in the most recent reporting period — combined with upward-trending analyst estimates suggest the company is consistently outperforming expectations and building a constructive earnings trajectory.
→Stable- Expectation
- The company delivers at least one additional earnings beat in the next two reporting periods, sustaining the positive surprise pattern.
CounterThe single miss in the last four quarters came in at roughly 21% below estimates, demonstrating that earnings can disappoint sharply; a repeat, particularly in a name carrying 15% short interest, could trigger an outsized negative reaction.
At $209.75, the stock is trading above the analyst consensus target of $207.56, meaning the near-term risk/reward geometry is unfavorable; the setup suggests patience rather than initiating new exposure at current prices.
→Stable- Expectation
- Analyst consensus price targets rise above $230 within two quarterly revision cycles following continued earnings beats, restoring meaningful positive upside.
CounterStrong technical momentum — golden cross, price above all key moving averages, RSI at 68, and rising on-balance volume — suggests institutional buyers continue to push the stock higher and that consensus targets may be stale rather than a binding ceiling.
▸ Show 1 more pillar▾ Show fewer
Free cash flow converts at approximately 128% of net income and the Piotroski F-Score of 7 out of 9 reflects a financially healthy balance sheet; the cash generation quality provides a buffer against potential reimbursement headwinds.
→Stable- Expectation
- FCF-to-net-income conversion ratio stays above 100% for the next four quarters, confirming that cash generation remains resilient.
CounterGross margins score among the weakest components of the quality assessment; if reimbursement conditions tighten, the FCF conversion advantage could narrow quickly, limiting the financial buffer the current quality metrics appear to provide.
→ Full pillar scorecard with all 4 pillars + per-dimension breakdown
When this thesis breaks
Falsifiable conditions per pillar — any one trip warrants review independent of price action. Engine-derived; not personalized advice.
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Approximately 68% of revenue derives from government-based programs including Medicare and Medicare Advantage, meaning any adverse policy change or reimbursement-rate adjustment by government payers could have a disproportionately large impact on profitability.
Trip ifGovernment-based program revenue falls below 60% of total revenue for 2 consecutive reporting periods.
- P2Three earnings beats in the last four quarters — including a 23% positive surprise in the most recent reporting period — combined with upward-trending analyst estimates suggest the company is consistently outperforming expectations and building a constructive earnings trajectory.
Trip ifEPS surprise falls below 0% for 2 consecutive quarters, ending the recent beat cadence.
- P3At $209.75, the stock is trading above the analyst consensus target of $207.56, meaning the near-term risk/reward geometry is unfavorable; the setup suggests patience rather than initiating new exposure at current prices.
Trip ifAnalyst consensus price target rises above $235 within 4 quarterly revision cycles, restoring more than 12% upside from current price.
- P4Free cash flow converts at approximately 128% of net income and the Piotroski F-Score of 7 out of 9 reflects a financially healthy balance sheet; the cash generation quality provides a buffer against potential reimbursement headwinds.
Trip ifFCF-to-net-income conversion ratio falls below 80% for 2 consecutive quarters.
How the engine reached this verdict
TrendMatrix's engine output for DaVita Inc. (DVA) is HOLD_IF_HOLDING with medium conviction, score 5.6/10 at $213.04. The F-path SELL output reflects an overall score of 4.1 below the 5.4 soft trigger — multiple weakening dimensions accumulated rather than a single hard-floor breach. Asymmetry R:R of -1.68 is supplementary context, not the trigger.
HOLD flips toward BUY_WAIT if reward-to-risk (NEGATIVE) clears AND a co-confirming gate triggers. HOLD flips toward SELL if any of the currently-passing gates drop below threshold OR three or more dimensions fall below 4 simultaneously.
The engine is not issuing fresh-money entry targets at the current verdict. The technical entry zone is around — with a technical stop near $202.02 for existing positions. Asymmetric R:R is -0.17, below the threshold (≥2.0) at which the engine would actively flag fresh capital. The engine's sizing output: 0.5% of portfolio at this asymmetry level (none-conviction tier).
On the bull side: Strong earnings beat streak (3/4); Earnings estimates trending UP; Attractive valuation. On the bear side: Concentration risk — Customer: Medicare and Medicare Advantage plans (57.0%); Concentration risk — Customer: total government-based programs (68.0%); Analyst target reached - limited upside remaining. Active engine warnings: V8: Target reached (-20.9% upside), L3:NEWS_MOD=+1: SELL_IF_HOLDING → HOLD_IF_HOLDING, V9 Gate Failed: ASYMMETRY:-1.7=NEGATIVE.
For the full 10-dimension breakdown + V9 gate detail: Why TrendMatrix rates DVA — 10-dimension breakdown →
Bull case
- ▸Strong earnings beat streak (3/4)
- ▸Earnings estimates trending UP
- ▸Attractive valuation
Bear case
- ▸Concentration risk — Customer: Medicare and Medicare Advantage plans (57.0%)
- ▸Concentration risk — Customer: total government-based programs (68.0%)
- ▸Analyst target reached - limited upside remaining